Shopping Cart
- Remove All
- Your shopping cart is currently empty
PAT-048 is an effective and selective autotaxin inhibitor. PAT-048 reduces dermal fibrosis in vivo. PAT-048 also inhibits IL-6 mRNA expression but displays no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in the lung fibrosis model. PAT-048 has an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 1.586 € | 6-8 weeks | |
50 mg | 2.071 € | 6-8 weeks | |
100 mg | 2.660 € | 6-8 weeks |
Description | PAT-048 is an effective and selective autotaxin inhibitor. PAT-048 reduces dermal fibrosis in vivo. PAT-048 also inhibits IL-6 mRNA expression but displays no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in the lung fibrosis model. PAT-048 has an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. |
Targets&IC50 | ATX (mouse plasma): 200 nM(IC90), ATX (mouse plasma):20 nM |
Molecular Weight | 461.91 |
Formula | C22H18ClF2N3O2S |
Cas No. | 1359983-15-5 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.